Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vunakizumab (Anti-Human IL17A Recombinant Antibody), a recombinant human IgGκ monoclonal antibody, specifically targets and inhibits IL-17A's interaction with its receptor, making it useful for researching autoimmune conditions including psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Vunakizumab (Anti-Human IL17A Recombinant Antibody), a recombinant human IgGκ monoclonal antibody, specifically targets and inhibits IL-17A's interaction with its receptor, making it useful for researching autoimmune conditions including psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1]. |
Molecular Weight | N/A |
CAS No. | 1792181-33-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vunakizumab 1792181-33-9 inhibitor inhibit